12 Health Care Stocks Moving In Friday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Friday's pre-market session, several healthcare stocks experienced significant movements. NexImmune (NEXI) saw a dramatic increase of 343.1%, while Altimmune (ALT) and Biora Therapeutics (BIOR) also posted substantial gains. Conversely, Ampio Pharmaceuticals (AMPE) and LumiraDx (LMDX) led the decliners with significant drops in their stock prices.
December 01, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altimmune's stock increased by 35.44% to $4.28, with a market cap of $229.9 million.
Altimmune's notable pre-market rise indicates positive investor sentiment and could lead to a short-term uptrend, possibly driven by favorable company developments or market conditions.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Biora Therapeutics' stock rose by 32.25% to $1.64, with a market value of outstanding shares at $38.2 million.
The significant increase in Biora Therapeutics' stock price suggests a positive short-term outlook, potentially due to recent company achievements or favorable industry news.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
NexImmune's stock surged by 343.1% to $10.99, with a market value of outstanding shares at $11.6 million.
The substantial pre-market gain for NexImmune suggests a very positive short-term impact on the stock price, likely due to a significant catalyst such as positive clinical trial results, strategic partnerships, or other company-specific news.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Ampio Pharmaceuticals' shares fell by 32.6% to $3.88, with a market value of outstanding shares at $3.2 million.
Ampio Pharmaceuticals' significant pre-market decline is likely to have a negative short-term impact on the stock, possibly due to disappointing company news, negative clinical trial results, or broader market trends.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
LumiraDx's shares dropped by 30.85% to $0.12, with a market value of outstanding shares at $38.0 million.
The steep decline in LumiraDx's stock price indicates a negative short-term impact, which could be the result of adverse company news, regulatory challenges, or negative market sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100